Category: Portfolio News

Achronix now shipping industry’s highest performance Speedster7t FPGA devices

Achronix now shipping industry’s highest performance Speedster7t FPGA devices

Santa Clara, Calif., April 8, 2021 – Achronix Semiconductor Corporation, a leader in high-performance FPGAs and embedded FPGA (eFPGA) IP, today announced that it has begun shipping its 7nm Speedster®7t AC7t1500 FPGAs to customers ahead of schedule. The Speedster7t family is purpose-built for high bandwidth workloads in a broad range

Read More
ABL Space raises $170m growth equity round led by T. Rowe Price funds

ABL Space raises $170m growth equity round led by T. Rowe Price funds

EL SEGUNDO, Calif., March 25, 2021 /PRNewswire/ -- ABL Space Systems has closed a Series B investment round of $170 million at a valuation of $1.3 billion. The round was led by funds and accounts advised by T. Rowe Price Associates, Inc. Participation in the round included existing ABL investors

Read More
Ventyx Biosciences doses first subject in a Phase 1 Trial of VTX-958, a selective allosteric TYK2 Inhibitor for Autoimmune Diseases

Ventyx Biosciences doses first subject in a Phase 1 Trial of VTX-958, a selective allosteric TYK2 Inhibitor for Autoimmune Diseases

Study to evaluate pharmacokinetics, safety and tolerability of VTX-958 as well as effects on biomarkers of TYK2-driven inflammatory signaling ENCINITAS, March 16, 2021 /PRNewswire/ —  Ventyx Biosciences, Inc. a clinical-stage biotechnology company developing oral, small molecule therapeutics for autoimmune disease, today announced the dosing of the first subject in a

Read More
iCAD – New research supporting ProFound AI presented at European congress of radiology online meeting

iCAD – New research supporting ProFound AI presented at European congress of radiology online meeting

iCAD showcased expanded ProFound AI platform, including ProFound AI Risk, the world’s first clinical decision support tool that provides a highly accurate short-term risk estimation specific to each woman. NASHUA, N.H. – March 8, 2021 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and

Read More
Isorg obtains FBI certification for security market’s first organic photodiode-based module for fingerprint scanners

Isorg obtains FBI certification for security market’s first organic photodiode-based module for fingerprint scanners

US approval of FAP 10 module, first in a new category of optical sensors, is approbation that global biometrics market is ready for organic electronics in security applications. Limoges, France, March 8, 2021 – Isorg, a pioneer in organic photodetectors (OPDs) and large-area image sensors, today announces its Fingerprint Acquisition

Read More
iCAD announces closing of $25.0 million public offering of common stock and full exercise of underwriters’ option to purchase additional shares

iCAD announces closing of $25.0 million public offering of common stock and full exercise of underwriters’ option to purchase additional shares

NASHUA, N.H., March 08, 2021 -- iCAD, Inc. (the “Company”, NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the closing on March 5, 2021 of its previously announced underwritten public offering of 1,393,738 shares of common stock at a public offering price

Read More
ProterixBio announces commercial availability of a quantitative COVID-19 serology test validated for dried blood spots from a finger stick

ProterixBio announces commercial availability of a quantitative COVID-19 serology test validated for dried blood spots from a finger stick

Billerica, MA, February 11, 2020: ProterixBio, Inc. announced today commercial availability of a quantitative COVID-19 serology assay that has been validated for dried blood spots (DBS) from a finger stick. This is an update to the previously released SARS-CoV-2 (RBD) IgG Antibody test and is being offered as a testing

Read More
DataCore Software acquires Caringo, Inc.

DataCore Software acquires Caringo, Inc.

DataCore Software, the authority on software-defined storage, today announced that it has acquired Caringo, Inc. The combined entity will enable DataCore to offer complete, best-of-breed software-defined storage solutions for block, file, and object—from a single vendor. The acquisition will also add talent and expertise to the DataCore team, as well

Read More
NorthSea Therapeutics reports Positive Phase 2b interim results for icosabutate in NASH patients

NorthSea Therapeutics reports Positive Phase 2b interim results for icosabutate in NASH patients

Icosabutate demonstrates potent anti-inflammatory, anti-fibrotic and antioxidant properties, and shows improvement in cardio-metabolic risk profile Interim readout based on the first 90 patients treated for 16 weeks Once-daily oral icosabutate showed dose-dependent, significant, and clinically meaningful improvements in all liver function chemistry, and inflammatory and fibrotic biomarkers with a remarkable

Read More
TigerConnect acquires Critical Alert

TigerConnect acquires Critical Alert

SANTA MONICA, California — January 6, 2021 — TigerConnect®, healthcare’s most advanced, reliable, and widely adopted care team collaboration solution, today announced the acquisition of Critical Alert®, a leading provider of enterprise-grade middleware for hospitals and health systems. Critical Alert’s product suite consists of a middleware suite of products as

Read More
Resolve Therapeutics announces clinically meaningful improvement in patients with Systemic lupus erythematosus in Phase 2a clinical trial

Resolve Therapeutics announces clinically meaningful improvement in patients with Systemic lupus erythematosus in Phase 2a clinical trial

Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced results from its Phase 2a study of RSLV-132 in patients with Systemic lupus erythematosus (SLE). Sixty-six patients diagnosed with SLE and a CLASI score of ≥ 10 at screening were enrolled into the study at 19 clinical

Read More
Resolve Therapeutics publishes positive Sjogren’s syndrome clinical trial results

Resolve Therapeutics publishes positive Sjogren’s syndrome clinical trial results

Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced publication of results from its Phase 2 study of RSLV-132 for the treatment of primary Sjogren’s syndrome (pSS).  The work was published in the leading rheumatology journal, Arthritis and Rheumatology (doi.org/10.1002/art.41489).  The Phase 2 study demonstrated a

Read More